CD274 and non-small cell lung carcinoma: Finally, PD-L1 inhibitors have shown greater efficacy and tolerability compared to other classes of ICIs and, among those approved by the FDA, we mention atezolizumab, durvalumab, and avelumab, mainly used for the treatment of urothelial carcinoma [72,73], non-small cell lung cancer (NSCLC) [74,75], and Merkel cell carcinoma [76].